The Institute for Clinical and Economic Review (ICER) is set to evaluate AstraZeneca’s tezepelumab. ICER will consider the efficacy and value of the asthma drug. The Food and Drug Administration is expected to rule on the drug later this year or early 2022.
“The assessment will be publicly discussed during a meeting of the Midwest CEPAC (Midwest CEPAC) in November 2021, where the independent evidence review panel will deliberate and vote on evidence presented in ICER’s report…. In addition to comments on the scope, ICER also welcomes submissions from stakeholders on examples of low-value care practices within this clinical area. These submissions will inform a report section focused on strategies to reduce waste and preserve resources for high-value, potentially higher-cost treatments.” Read more here.
(Source: ICER, 5/6/2021)